drugset / Trial / NCT03831880

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD

NCT03831880

Phase 3 Completed 87 enrolled Pfizer
RandomizedCrossoverOpen-labelOther

Summary

This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.

Timeline

Start
2019-02-07
Primary completion
2020-08-28
Completion
2020-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatrogon Protein / enzyme biologic 0.66 mg/kg Subcutaneous
Subject Somatropin Protein / enzyme biologic Subcutaneous

Indications